Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a DNA damage response inhibitor with or without anti-PD-L1 immunotherapy in patients with neoadjuvant-trea…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors [EARLY_Phase 1]
Early-phase study update on intratumoral microdose administration of PBA-0405 in solid tumors; the trial status is completed.
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours [Phase 1, Phase 2]
Cancer Research UK reported an ongoing Phase 1/2a trial of HMBD-001 in HER3-positive solid tumors; the study is currently Active Not Recruit…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors [EARLY_Phase 1]
Phase 0 multicenter study evaluating pharmacodynamic effects of intratumoral microdosing with PBA-0111 in solid tumors; the trial is current…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1]
Phase 1, first-in-human dose-finding and expansion study of XmAb808 in combination with pembrolizumab in advanced solid tumors; the trial ha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer [Phase 2]
Biocad's BCD-236 is being studied in combination with chemotherapy for relapsed and/or metastatic triple-negative breast cancer in a Phase 2…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Triple Negative Breast Cancer and Celecoxib. Pilot Study [Phase 2]
This is a Phase 2 pilot clinical trial evaluating celecoxib in combination for triple-negative breast cancer and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC [Phase 2]
A prospective multicenter Phase 2 single-arm trial evaluating AK112 plus nab-paclitaxel and carboplatin as neoadjuvant therapy for triple-ne…
-
CLINICAL_TRIALS research · 2025-08-03Clinical Trial Update: A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). [Phase 2]
Phase 2 randomized neoadjuvant trial evaluating JS004 plus toripalimab with chemotherapy versus toripalimab with chemotherapy and chemothera…
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative [NA]
This clinical trial update describes using molecular testing and imaging to improve response in patients with stage I-III triple-negative br…
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: MGC018 With or Without MGA012 in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports results from the combination of MGC018 with or without MGA012 (pembrolizumab) in advanced solid tumors. T…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment
The clinical trial NCT05435352 evaluating image-based AI predictive biomarkers for precision neoadjuvant treatment in triple-negative breast…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs [Phase 2]
A Phase 2 trial of datopotamab deruxtecan (DATO-BASE) for breast cancer with brain metastases is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer [NA]
Clinical trial update on zoledronic acid combined with the EC-T chemotherapy regimen for metastatic triple-negative breast cancer; the study…
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC [Phase 2]
A Phase 2 clinical trial update evaluating Sacituzumab tirumotecan for neoadjuvant therapy in early-stage triple-negative breast cancer; the…
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Clinical trial update reports on the combination of copanlisib and eribulin in metastatic triple-negative breast cancer in Phase 1/2, with r…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) [Phase 1, Phase 2]
A Phase 1/2 START trial evaluating the combination of selinexor and talazoparib in advanced refractory solid tumors and triple-negative brea…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial testing pembrolizumab combined with ADG106 for advanced solid tumors and triple-negative breast cancer is c…
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer [Phase 1]
Phase 1 safety data for Tinengotinib (TT-00420) as monotherapy in patients with advanced solid tumors and triple-negative breast cancer has …
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors [Phase 1]
A Phase 1 trial of NM32-2668 in adults with selected advanced solid tumors has been terminated. The study enrolled multiple tumor types incl…
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating deferoxamine in combination with chemotherapy for metastatic triple-negative breast cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-07-21Clinical Trial Update: Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating the combination of chidamide and zimberelimab for metastatic tri…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating inosine to reverse chemotherapy resistance in triple-negative breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
NuCana plc announced termination of a Phase 1/2 trial evaluating NUC-3373 in combination with other agents for patients with advanced solid …
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. [Phase 2]
Phase 2 clinical trial evaluating PSMA-PET/CT to assess PSMA expression in patients with progressive triple-negative breast cancer; recruitm…